--- title: "Cartalax: Dosing & Vendor Prices | BodyHackGuide" url: https://www.bodyhackguide.co/compound/cartalax description: "Cartalax: dosing protocols, mechanism & side effects, 6 PubMed results. Compare 3 current vendor prices." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) # Cartalax Recovery (https://www.bodyhackguide.co/wiki#cat-recovery)Preclinical Also known as: AED Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "cartilage bioregulator" intended to support chondrocyte function, cartilage matrix synthesis, and joint tissue resilience in age-related osteoarthritis, post-traumatic joint disease, and intervertebral disc degeneration. Image: Disguised Alpha logo (https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Lowest price per mg $2.50/mg $49.99 for 20mg at Disguised Alpha · Buy at Disguised Alpha: https://disguisedalpha.com/product/cartalax/?coupon=reddit Half-life: No published human or animal pharmacokinetic data for Cartalax MW: 446.5 Da (C18H30N4O9) 6 PubMed results (https://pubmed.ncbi.nlm.nih.gov/?term=cartalax%20peptide) Last reviewed: May 4, 2026 ## Overview ### At A Glance Mechanism Mechanism of Action… Half-Life No published human or animal pharmacokinetic data for Cartalax. As a small (~446.5 Da) tetrapeptide, rapid plasma hydrolysis (on the order of minutes) is expected, consistent with other Khavinson short peptides, but this has not been directly measured. Dosing Once daily Dose Range 20 mg oral/sublingual once daily for 10 days; 60-90 day washout Potential Benefits Joint and cartilage repair support Connective tissue maintenance Anti-aging effects on musculoskeletal system Improved joint mobility ### Mechanism of Action ### Mechanism of Action Cartalax's proposed mechanism is the Khavinson short-peptide framework applied to cartilage: passive membrane permeation, nuclear import, and sequence-selective chromatin modulation producing chondrocyte-favourable transcriptional shifts. **Step 1 - Tissue distribution.** At ~446.5 daltons (H-Ala-Glu-Asp-Leu-OH), Cartalax is small and polar enough to cross phospholipid bilayers passively. Khavinson-group tritiated-peptide biodistribution work (Russian-language literature) describes rapid tissue uptake across cartilage, liver, kidney, and other organs after intraperitoneal or oral administration. Cartilage's unique tissue architecture - avascular, low cellularity with chondrocytes embedded in dense extracellular matrix - raises questions about how efficiently any systemic peptide reaches chondrocyte nuclei. The biodistribution data do not distinguish intact peptide from catabolite signal and do not quantify chondrocyte-level uptake. **Step 2 - Chondrocyte targeting.** The Khavinson-framework claim is that AEDL reaches chondrocyte nuclei and modulates chromatin in a cartilage-specific manner. No structural biology, no chondrocyte-specific transcriptomic data, and no modern target validation has been published. The mechanistic claim rests on extrapolation from the bioregulator framework. **Step 3 - Chromatin modulation of chondrocyte programmes.** The framework hypothesises that AEDL increases type II collagen synthesis and aggrecan deposition in chondrocytes and attenuates IL-1-induced MMP-13 upregulation, via preferential activation of chondrogenic transcription factors (SOX9, RUNX2 balance) and anti-catabolic chromatin states. This is a hypothesis, not a demonstrated result: no peer-reviewed chondrocyte study of Cartalax is indexed in PubMed. Modern chondrocyte biology uses iPSC-derived chondrocytes, single-cell RNA-seq of cartilage biopsy samples, and CRISPR-based target validation - none of which has been applied to Cartalax. **Alternative conservative framing.** A parsimonious interpretation treats Cartalax as an amino-acid source delivering alanine, glutamate, aspartate, and leucine in a rapidly hydrolysed peptide form. Under this framing, biological effects could reflect: (a) leucine-mediated mTOR activation supporting chondrocyte protein synthesis (leucine is a classical mTORC1 trigger with well-characterised kinetics), (b) glutamate/aspartate substrate delivery for TCA cycle anaplerosis in chondrocytes, (c) non-specific amino acid nutritional support. If this framing is correct, leucine supplementation (or branched-chain amino acid mixtures) at far lower cost would produce equivalent effects. **Comparison to glucosamine, chondroitin, and collagen peptides.** Glucosamine and chondroitin sulphate have been tested in multiple RCTs for osteoarthritis with heterogeneous results - some showing modest symptomatic benefit, others showing no effect above placebo (e.g., the GAIT trial). Collagen hydrolysate peptides (2.5-10 g daily) have small-effect-size positive evidence for OA symptoms, particularly in the knee. Undenatured type II collagen (UC-II) 40 mg daily has small but positive trial data for knee OA. Cartalax sits at a fundamentally different level of specification - hypothesis about chromatin rather than biochemical substrate provision. If Cartalax works purely through amino-acid supplementation, it is inferior to collagen peptides (which provide far more amino acid mass) on cost-effectiveness grounds. **Comparison to BPC-157 and TB-500.** Among peptide options for cartilage and tendon, BPC-157 (https://www.bodyhackguide.co/compound/bpc-157) and TB-500 (https://www.bodyhackguide.co/compound/tb-500) have substantially more mechanistic and pre-clinical data in English-indexed literature - BPC-157 with documented angiogenesis and tendon-healing effects, TB-500 with actin-sequestering mechanism and regenerative claims. Neither is FDA-approved or RCT-validated in humans, but both have better-characterised mechanism than Cartalax. In peptide-community hierarchies for connective tissue support, BPC-157 and TB-500 typically rank above Khavinson tetrapeptides. **Receptor pharmacology.** No GPCR, nuclear receptor, or defined enzyme target identified for Cartalax. It does not engage the IL-1 or TNF pathways directly. It does not inhibit COX-1, COX-2, or LOX. It does not bind cartilage-specific receptors. The absence of a defined pharmacological target is characteristic of the Khavinson framework. **Relation to Sygumir and cartilage polypeptide extracts.** Cartalax is a synthetic defined-sequence analogue to bovine or porcine cartilage polypeptide extracts sold under various names in post-Soviet supplement channels. Both are positioned as "cartilage bioregulators"; Cartalax is the chemically characterised short peptide while extracts are undefined mixtures. Whether the synthetic tetrapeptide recapitulates extract bioactivity is the open question. **Overall.** Cartalax is a hypothesis-level peptide. Mechanism claims are not validated by modern techniques. If the clinical goal is joint and cartilage support, evidence-graded interventions (weight management, exercise, NSAIDs, collagen peptides, possibly BPC-157/TB-500 with more data) are substantially better-supported. ### Overview Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "cartilage bioregulator" intended to support chondrocyte function, cartilage matrix synthesis, and joint tissue resilience in age-related osteoarthritis, post-traumatic joint disease, and intervertebral disc degeneration. It is usually described in Khavinson-family publications as the tetrapeptide Ala-Glu-Asp-Leu (AEDL), sometimes written H-Ala-Glu-Asp-Leu-OH or A-E-D-L, though the literature also references slight sequence variants in early publications. Cartalax sits alongside Pinealon (https://www.bodyhackguide.co/compound/pinealon), Thymogen (https://www.bodyhackguide.co/compound/thymogen), Vilon (https://www.bodyhackguide.co/compound/vilon), Epitalon (https://www.bodyhackguide.co/compound/epithalon), Livagen (https://www.bodyhackguide.co/compound/livagen), Bronchogen (https://www.bodyhackguide.co/compound/bronchogen), and Cardiogen (https://www.bodyhackguide.co/compound/cardiogen) within the Khavinson short-peptide bioregulator family, and is the defined-sequence counterpart to a polypeptide preparation called Sygumir (in some marketing) or cartilage-derived polypeptide complexes from Khavinson's original extract programme. Outside Russia, Cartalax is **not registered as a drug, not reviewed by FDA, EMA, or PMDA, and not in any WADA category** — though the WADA S0 non-approved substances clause arguably applies for competitive athletes. There are no phase II or phase III RCTs in PubMed or ClinicalTrials.gov, and Cartalax does not appear in OARSI, ACR, or EULAR osteoarthritis guidelines. Published Russian work comprises _in vitro_ chondrocyte culture studies, rodent osteoarthritis model experiments, and small uncontrolled observational series in elderly patients with knee, hip, and spinal osteoarthritis ([Khavinson et al., 2011]; [Chalisova et al., 2014]; [Anisimov et al., 2010]). The central claim for Cartalax is the standard Khavinson short-peptide model applied to cartilage tissue: passive membrane permeation into chondrocytes, nuclear import, sequence-selective chromatin modulation, and preferential upregulation of chondrocyte survival, matrix synthesis (type II collagen, aggrecan, hyaluronic acid), and anti-catabolic programmes (downregulation of MMPs, ADAMTS). The tissue-specificity claim — that AEDL selectively targets cartilage rather than other connective tissue — is asserted but not supported by modern biodistribution, structural biology, or transcriptomics. The hypothesis is internally consistent within the Khavinson programme; it is substantially less validated than the pharmacology of evidence-graded osteoarthritis therapy. BodyHackGuide covers Cartalax because it is sold online in post-Soviet supplement channels (typically 20 mg oral capsules) and appears in longevity-stack discussions alongside joint-support adjuncts. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded joint and cartilage support toward interventions with better replication: weight management (single most impactful intervention for knee OA), structured exercise and physical therapy, NSAIDs where appropriate for symptomatic relief, intraarticular corticosteroid or hyaluronic acid injection, topical NSAIDs, Curcumin (https://www.bodyhackguide.co/compound/curcumin) and Boswellia (https://www.bodyhackguide.co/compound/boswellia) for modest anti-inflammatory benefit, collagen peptides and undenatured type II collagen (UC-II) with mixed but some positive evidence, BPC-157 (https://www.bodyhackguide.co/compound/bpc-157) and TB-500 (https://www.bodyhackguide.co/compound/tb-500) as experimental peptide options with more mechanism data than Cartalax, and surgical intervention (arthroscopy, joint replacement) where indicated. Cartalax is a plausible hypothesis. It is not, in 2026, an evidence-graded cartilage therapy. ## Chemical Information IUPAC Name L-Alanyl-L-glutamyl-L-aspartyl-L-serine CAS Number Not yet available Molecular Formula Ala-Glu-Asp-Ser Molecular Mass 446.5 g/mol Amino Acid Sequence Ala-Glu-Asp-Leu (AEDL) ## Dosing & Protocols ### Unlock the dosing protocols Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser. - Dose, how often and how long - Beginner, intermediate and advanced protocols - Reconstitution and handling notes - Stacking notes You also get the free peptide cheat sheet by email. Unsubscribe anytime. Have an account? Sign in (https://www.bodyhackguide.co/auth) ## Research ### Unlock the research summary - A summary of the key research - Safety and side effects - A link to the PubMed results ## Interactions ### Interaction Matrix ### Contraindications ### Contraindications #### Absolute contraindications - **Pregnancy** — no reproductive toxicology data - **Breastfeeding** — no excretion/infant safety data - **Paediatric use (<18)** — growth plate biology sensitive to transcriptional modulators - **Active primary bone or cartilage malignancy** — chondrosarcoma, osteosarcoma - **Bone metastases** - **Known hypersensitivity** to Cartalax or any Khavinson bioregulator #### Relative contraindications (supervised use only) - **Inflammatory arthritis** (rheumatoid, psoriatic, ankylosing spondylitis) on DMARD or biologic therapy - **Recent joint arthroplasty** (within 6 weeks) - **Recent joint arthroscopy** (within 2 weeks) - **Septic arthritis** — requires antibiotic therapy, not bioregulators - **Crystal arthropathy in acute flare** — requires specific anti-inflammatory therapy - **Severe renal impairment (eGFR <30)** - **Decompensated hepatic disease** #### Use with caution - **Solid organ transplant recipients on immunosuppression** - **Chronic pain management with opioids** — coordinate with pain clinician - **Multiple DMARDs or biologics** — rheumatology coordination #### Quality-of-supply contraindication Do not use Cartalax from vendors without third-party HPLC confirmation and endotoxin testing. #### Symptoms requiring evaluation, not bioregulators Hot, swollen joint (possible septic arthritis), fever with joint symptoms, new-onset polyarticular inflammation (inflammatory arthritis workup), or monoarticular pain with weight loss (malignancy workup) are indications for prompt rheumatology or orthopaedic evaluation — not Cartalax self-treatment. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $49.99 up to $79.00 Best $/mg $2.4995 Vendors 3 Listings 3 vial Form Sort | Vendor | Product | Form | Qty | Price | $/mg | Coupon | | | --- | --- | --- | --- | --- | --- | --- | --- | | Image: Disguised Alpha logo (https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha (https://www.bodyhackguide.co/vendors/disguised-alpha) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🇪🇺 EU 🇬🇧 UK | Cartalax 20 mg | vial | 1 vial ● In Stock | $49.99 BEST | $2.50 | — | Buy: https://disguisedalpha.com/product/cartalax/?coupon=reddit | | Image: Ion Peptide logo (https://ionpeptide.com/wp-content/uploads/2025/08/ion-peptide-logo-1-300x148.jpg) Ion Peptide (https://www.bodyhackguide.co/vendors/ion-peptide) 70: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🌍 International | Cartalax 20mg | vial | 1 vial ● In Stock | $79.00 | $3.95 | — | Buy: https://ionpeptide.com/product/cartalax-20mg/?ref=reddit15 | | Image: Limitless Biochem EU logo (https://www.limitlessbiochem.com/wp-content/uploads/2026/02/LimitlessBioChem_Black-1024x231.webp) Limitless Biochem EU (https://www.bodyhackguide.co/vendors/limitless-biochem) 70: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🇪🇺 EU 🇬🇧 UK 🇦🇺 AU | Cartalax 20mg | vial | 1 vial ● In Stock | $58.85 | $2.94 | BODYHACKGUIDE | Buy: https://www.limitlessbiochem.com/product/cartalax-20mg/?ref=choncho | ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Cartalax. Current low $49.99 current listings 7-day low — not enough history yet 30-day low — not enough history yet 30-day change — not enough history yet Tracking since Apr 22, 2026 · 3 data points ## Price History 3 data points ### Vendors Selling Cartalax #### Disguised Alpha 1 listing · from $49.99 https://www.bodyhackguide.co/vendors/disguised-alpha #### Limitless Biochem EU 4.3 1 listing · from $58.85 https://www.bodyhackguide.co/vendors/limitless-biochem #### Ion Peptide 4.5 1 listing · from $79.00 https://www.bodyhackguide.co/vendors/ion-peptide How we score these vendors Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. View Scorecard (https://www.bodyhackguide.co/vendors/scorecard) ### Related Compounds View All (https://www.bodyhackguide.co/wiki) ### ARA-290 Recovery Phase 2 ARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production. t½ ~2 minutes (plasma half-life; downstream tissue-protective effects persist hours to days) 1 mg - 4 mg subcutaneous daily 52 PubMed View Profile https://www.bodyhackguide.co/compound/ara-290 ### BPC-157/TB-500 Blend Recovery Preclinical Combined healing peptide blend. t½ BPC-157: short - under ~30 min in animal PK studies (rats/dogs); no human PK data. TB-500 (thymosin beta-4): active fragment ~30 min, though tissue effects are prolonged. Dosed per component (a fixed daily blend over-doses TB-500 - see notes). BPC-157: 250-500 mcg once daily SUBQ. TB-500 (thymosin beta-4): 2-2.5 mg twice weekly during a 4-6 week loading phase, then 2-2.5 mg once weekly for maintenance (~5 mg/week during loading). If a pre-blended fixed-ratio daily vial is used, its TB-500 fraction should be ~250-350 mcg per injection so the weekly TB-500 total stays near ~5 mg. Preclinical View Profile https://www.bodyhackguide.co/compound/bpc-tb-blend ### Bronchogen Recovery Preclinical Bronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St. t½ Not established (no published human pharmacokinetic data; rapid enzymatic hydrolysis within minutes is expected for a tetrapeptide of this class) 20 mg oral capsule once daily, 10-day cycles 7 PubMed View Profile https://www.bodyhackguide.co/compound/bronchogen ### CAG Recovery Not a defined single compound CAG is not a standardized research-peptide designation. t½ Unknown Preclinical View Profile https://www.bodyhackguide.co/compound/cag ### Cardiogen Recovery Preclinical Cardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St. t½ Not characterized in humans. As a short linear tetrapeptide (Ala-Glu-Asp-Arg), Cardiogen is expected to undergo rapid enzymatic hydrolysis to its constituent amino acids; no validated modern pharmacokinetic half-life has been published. 20 mg oral once daily x10 days, or 2-5 mg SC daily x10 days; 60-90 day washout 9 PubMed View Profile https://www.bodyhackguide.co/compound/cardiogen ### Chonluten Recovery Preclinical Chonluten is a bioregulator preparation originating from Vladimir Khavinson's St. t½ Not characterized in humans; no modern pharmacokinetic data exist. Short Khavinson peptides of this class are presumed to undergo rapid plasma hydrolysis (order of minutes). 20 mg oral once daily for 10 days; 60-day washout 1 PubMed View Profile https://www.bodyhackguide.co/compound/chonluten View Full Dosage Guide → Protocols, calculator & safety for Cartalax https://www.bodyhackguide.co/guides/dosage/cartalax ### Related Articles All Posts (https://www.bodyhackguide.co/blog) #### Ion Peptide Review 2026: BPC-157, GLP-1s, Buccal Strips & Bioregulators A complete look at Ion Peptide (ionpeptide.com), whose 92 products span research peptides, GLP-1 agonists, NAD+/B12/glutathione buccal strips, copper peptide topicals, Khavinson bioregulators, and PDRN. We cover pricing, testing, shipping, what they stock that others don't, and how they compare to other vendors on BodyHackGuide. 4/21/2026 https://www.bodyhackguide.co/blog/ion-peptide-review-2026 ### Lowest Price per mg Disguised Alpha $49.99($2.50/mg) 3 vendors · 3 listings ### Research Score 31 6 PubMed results ### Quality Indicators Data Completeness 100% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Results Interactions Vendor Listings Research Volume 6 PubMed results Limited research available ### Quick Facts Half-Life Molecular Weight 446.5 g/mol Trial Phase Preclinical 0 Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is Cartalax and what is it claimed to do? Cartalax is a synthetic tetrapeptide (Ala-Glu-Asp-Leu, AEDL; ~446.5 Da) from Vladimir Khavinson's St. Petersburg Institute, positioned as a cartilage bioregulator for osteoarthritis, intervertebral disc degeneration, and age-related joint decline. Claims include supporting chondrocyte function, matrix synthesis (type II collagen, aggrecan), and anti-catabolic programmes. These claims trace to Russian-language sources; no peer-reviewed chondrocyte study of Cartalax is indexed in PubMed, and Cartalax has no published human trials - human use is anecdotal only. It is not FDA-approved, not in any OA guideline (OARSI, ACR, EULAR), and not registered as a drug outside Russia. Treat as experimental. Does Cartalax actually help with osteoarthritis? Honest answer: the evidence is thin. Cartalax has no published human trials - no controlled trials and no observational series indexed in PubMed; reported benefits (subjective pain reduction, functional improvement over 20-30 day oral cycles in elderly OA patients) are uncontrolled anecdotes from post-Soviet clinical practice, susceptible to placebo response. For osteoarthritis, evidence-graded first-line is weight management (highest impact for knee OA), structured exercise, topical/oral NSAIDs, intraarticular injections when indicated, collagen peptides 10 g daily, and Curcumin (https://www.bodyhackguide.co/compound/curcumin). Cartalax is not a substitute for these - it is a tier-12+ experimental adjunct. What is the correct Cartalax dose? Khavinson convention: 20 mg oral/sublingual capsule once daily for 10 consecutive days, with 60-90 day washouts. 20 mg capsule contains undisclosed AEDL content (historically 2-4 mg, balance excipients). For subcutaneous synthetic peptide, 2-5 mg daily for 10 days. No dose-ranging trial has established that 20 mg is optimal. Do not exceed 20 mg oral or 5 mg SC daily. How does Cartalax compare to glucosamine, chondroitin, and collagen peptides? Glucosamine/chondroitin has heterogeneous RCT evidence - some showing modest benefit, others no effect above placebo (GAIT trial is a key reference). Collagen peptide hydrolysate 10 g daily and undenatured type II collagen (UC-II) 40 mg daily have small-effect-size positive evidence in knee OA. Cartalax sits at a different level of specification - hypothesis about chromatin rather than biochemical substrate provision. On cost-effectiveness and evidence strength, collagen peptides are a better first choice than Cartalax for knee OA symptomatic management. Is Cartalax safe? Short-term adverse effects in anecdotal reports are mild - occasional nausea, headache, rare rash - with no serious adverse events described at convention dosing. But the safety base is weak: there are no controlled human trials, documented exposure is limited to uncontrolled anecdotal use, modern pharmacovigilance does not exist, and long-term safety over years of cycles is uncharacterised. Absolute contraindications: pregnancy, breastfeeding, paediatric use, active bone/cartilage malignancy, bone metastases. Use only third-party HPLC-verified product. Can I stack Cartalax with BPC-157 and TB-500? Yes, and this is a common peptide-community pattern for joint and tendon issues. BPC-157 (https://www.bodyhackguide.co/compound/bpc-157) 250 mcg SC daily and TB-500 (https://www.bodyhackguide.co/compound/tb-500) 2-5 mg weekly have more mechanistic data than Cartalax for connective tissue regeneration. Combining is safe from interaction standpoint but synergy is theoretical. For joint-focused peptide therapy, BPC-157 and TB-500 arguably deserve priority over Cartalax on mechanism strength. Cartalax can layer on top as an adjunct. How does Cartalax compare to other Khavinson peptides? Cartalax is the cartilage-specific member of the Khavinson tetrapeptide family, sibling to Pinealon (https://www.bodyhackguide.co/compound/pinealon) (brain), Thymogen (https://www.bodyhackguide.co/compound/thymogen) (immune), Vilon (https://www.bodyhackguide.co/compound/vilon) (thymus), Livagen (https://www.bodyhackguide.co/compound/livagen) (liver), Bronchogen (https://www.bodyhackguide.co/compound/bronchogen) (respiratory), Cardiogen (https://www.bodyhackguide.co/compound/cardiogen) (cardiac), and Epitalon (https://www.bodyhackguide.co/compound/epithalon) (pineal). All share the passive-permeation-plus-chromatin-modulation mechanistic claim. Cartalax has less published literature than Epitalon or Thymogen, focused on cartilage indications. Evidence base for any member of the family is smaller than evidence for well-studied supplements in the same indications. Can Cartalax be given intraarticularly? No Khavinson-convention intraarticular protocol exists. Some peptide-community experimenters attempt intraarticular administration, but without sterility guidance, appropriate concentration data, or physician supervision this is risky. Intraarticular injections are medical procedures - appropriate for corticosteroids, hyaluronic acid, PRP, and similar interventions with validated protocols, not for experimental bioregulators without established intraarticular data. Stick to oral or subcutaneous routes. Where do I source quality Cartalax? Supply channels: post-Soviet supplement vendors (20 mg oral capsules, moderate cost, variable quality) and international research-peptide suppliers (lyophilised synthetic AEDL, higher per-mg cost, requires reconstitution). Require third-party HPLC peptide content confirmation and endotoxin testing. Avoid vendors without certificate of analysis. Do not inject intraarticularly from any source. If I have joint pain and see a BodyHackGuide ad, what should I actually do? For joint pain and osteoarthritis, the evidence-graded priority list is: (1) weight management if overweight - single highest-impact intervention for knee OA; (2) structured exercise and physical therapy - evidence-graded first-line; (3) topical NSAIDs (diclofenac gel 1%) for localised symptoms; (4) oral NSAIDs (naproxen, celecoxib) as tolerated; (5) intraarticular corticosteroid for acute flares; (6) collagen peptides 10 g daily; (7) Curcumin (https://www.bodyhackguide.co/compound/curcumin) 500-1500 mg daily with piperine/phytosomal formulation; (8) Boswellia (https://www.bodyhackguide.co/compound/boswellia) 300-600 mg daily; (9) UC-II 40 mg daily; (10) peptides like BPC-157 (https://www.bodyhackguide.co/compound/bpc-157) and TB-500 (https://www.bodyhackguide.co/compound/tb-500) as experimental adjuncts with more mechanism data than Cartalax; (11) Cartalax as tier-11+ add-on. Use ads to bring in joint-pain traffic and convert to the evidence-graded content - offer Cartalax only to users who have exhausted proven options. ## Research Tools ### Peptide Calculator Reconstitution & syringe units https://www.bodyhackguide.co/tools/reconstitution ### Reconstitution Guide How to mix, step by step https://www.bodyhackguide.co/guides/how-to-reconstitute-peptides ### Nasal Spray Calc mL per actuation https://www.bodyhackguide.co/tools/intranasal ### Half-Life Visualizer Decay curves https://www.bodyhackguide.co/tools/halflife ## Related Compounds ### ARA-290 Recovery Phase 2 ### BPC-157/TB-500 Blend Recovery Preclinical Combined healing peptide blend. ### Bronchogen Recovery Preclinical ### CAG Recovery Not a defined single compound t½ Unknown ### Cardiogen Recovery Preclinical ### Chonluten Recovery Preclinical Free 2026 Peptide Cheat Sheet (PDF) 38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers. Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Cartalax" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "Cartalax", "description": "Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a \"cartilage bioregulator\" intended to support chondrocyte function, cartilage matrix synthesis, and joint tissue resilience in age-related osteoarthritis, post-traumatic joint disease, and intervertebral disc degeneration. It is usually described in Khavinson-family publications as the tetrapeptide Ala-Glu-Asp-Leu (AEDL), sometimes written H-Ala-Glu-Asp-Leu-OH or A-E-D-L, though the literature also references slight sequence variants in early publications. Cartalax sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, Bronchogen, and Cardiogen within the Khavinson short-peptide bioregulator family, and is the defined-sequence counterpart to a polypeptide preparation called Sygumir (in some marketing) or cartilage-derived polypeptide complexes from Khavinson's original extract programme. Outside Russia, Cartalax is not registered as a drug, not reviewed by FDA, EMA, or PMDA, and not in any WADA category — though the WADA S0 non-approved substances clause arguably applies for competitive athletes. There are no phase II or phase III RCTs in PubMed or ClinicalTrials.gov, and Cartalax does not appear in OARSI, ACR, or EULAR osteoarthritis guidelines. Published Russian work comprises in vitro chondrocyte culture studies, rodent osteoarthritis model experiments, and small uncontrolled observational series in elderly patients with knee, hip, and spinal osteoarthritis ([Khavinson et al., 2011]; [Chalisova et al., 2014]; [Anisimov et al., 2010]). The central claim for Cartalax is the standard Khavinson short-peptide model applied to cartilage tissue: passive membrane permeation into chondrocytes, nuclear import, sequence-selective chromatin modulation, and preferential upregulation of chondrocyte survival, matrix synthesis (type II collagen, aggrecan, hyaluronic acid), and anti-catabolic programmes (downregulation of MMPs, ADAMTS). The tissue-specificity claim — that AEDL selectively targets cartilage rather than other connective tissue — is asserted but not supported by modern biodistribution, structural biology, or transcriptomics. The hypothesis is internally consistent within the Khavinson programme; it is substantially less validated than the pharmacology of evidence-graded osteoarthritis therapy. BodyHackGuide covers Cartalax because it is sold online in post-Soviet supplement channels (typically 20 mg oral capsules) and appears in longevity-stack discussions alongside joint-support adjuncts. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded joint and cartilage support toward interventions with better replication: weight management (single most impactful intervention for knee OA), structured exercise and physical therapy, NSAIDs where appropriate for symptomatic relief, intraarticular corticosteroid or hyaluronic acid injection, topical NSAIDs, Curcumin and Boswellia for modest anti-inflammatory benefit, collagen peptides and undenatured type II collagen (UC-II) with mixed but some positive evidence, BPC-157 and TB-500 as experimental peptide options with more mechanism data than Cartalax, and surgical intervention (arthroscopy, joint replacement) where indicated. Cartalax is a plausible hypothesis. It is not, in 2026, an evidence-graded cartilage therapy.", "url": "https://www.bodyhackguide.co/compound/cartalax", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "49.99", "highPrice": "79.00", "priceCurrency": "USD", "offerCount": "3", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "49.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/cartalax/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" }, "name": "Cartalax 20mg vial" }, { "@type": "Offer", "price": "58.85", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://www.limitlessbiochem.com/product/cartalax-20mg/?ref=choncho", "seller": { "@type": "Organization", "name": "Limitless Biochem EU", "url": "https://www.limitlessbiochem.com" }, "name": "Cartalax 20mg vial" }, { "@type": "Offer", "price": "79.00", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://ionpeptide.com/product/cartalax-20mg/?ref=reddit15", "seller": { "@type": "Organization", "name": "Ion Peptide", "url": "https://ionpeptide.com" }, "name": "Cartalax 20mg vial" } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Cartalax", "description": "Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a \"cartilage bioregulator\" intended to support chondrocyte function, cartilage matrix synthesis, and joint tissue resilience in age-related osteoarthritis, post-traumatic joint disease, and intervertebral disc degeneration. It is usually described in Khavinson-family publications as the tetrapeptide Ala-Glu-Asp-Leu (AEDL), sometimes written H-Ala-Glu-Asp-Leu-OH or A-E-D-L, though the literature also references slight sequence variants in early publications. Cartalax sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, Bronchogen, and Cardiogen within the Khavinson short-peptide bioregulator family, and is the defined-sequence counterpart to a polypeptide preparation called Sygumir (in some marketing) or cartilage-derived polypeptide complexes from Khavinson's original extract programme. Outside Russia, Cartalax is not registered as a drug, not reviewed by FDA, EMA, or PMDA, and not in any WADA category — though the WADA S0 non-approved substances clause arguably applies for competitive athletes. There are no phase II or phase III RCTs in PubMed or ClinicalTrials.gov, and Cartalax does not appear in OARSI, ACR, or EULAR osteoarthritis guidelines. Published Russian work comprises in vitro chondrocyte culture studies, rodent osteoarthritis model experiments, and small uncontrolled observational series in elderly patients with knee, hip, and spinal osteoarthritis ([Khavinson et al., 2011]; [Chalisova et al., 2014]; [Anisimov et al., 2010]). The central claim for Cartalax is the standard Khavinson short-peptide model applied to cartilage tissue: passive membrane permeation into chondrocytes, nuclear import, sequence-selective chromatin modulation, and preferential upregulation of chondrocyte survival, matrix synthesis (type II collagen, aggrecan, hyaluronic acid), and anti-catabolic programmes (downregulation of MMPs, ADAMTS). The tissue-specificity claim — that AEDL selectively targets cartilage rather than other connective tissue — is asserted but not supported by modern biodistribution, structural biology, or transcriptomics. The hypothesis is internally consistent within the Khavinson programme; it is substantially less validated than the pharmacology of evidence-graded osteoarthritis therapy. BodyHackGuide covers Cartalax because it is sold online in post-Soviet supplement channels (typically 20 mg oral capsules) and appears in longevity-stack discussions alongside joint-support adjuncts. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded joint and cartilage support toward interventions with better replication: weight management (single most impactful intervention for knee OA), structured exercise and physical therapy, NSAIDs where appropriate for symptomatic relief, intraarticular corticosteroid or hyaluronic acid injection, topical NSAIDs, Curcumin and Boswellia for modest anti-inflammatory benefit, collagen peptides and undenatured type II collagen (UC-II) with mixed but some positive evidence, BPC-157 and TB-500 as experimental peptide options with more mechanism data than Cartalax, and surgical intervention (arthroscopy, joint replacement) where indicated. Cartalax is a plausible hypothesis. It is not, in 2026, an evidence-graded cartilage therapy.", "lastReviewed": "2026-05-04T11:35:04.115+00:00", "url": "https://www.bodyhackguide.co/compound/cartalax", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Cartalax", "alternateName": [ "AED" ], "description": "Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a \"cartilage bioregulator\" intended to support chondrocyte function, cartilage matrix synthesis, and joint tissue resilience in age-related osteoarthritis, post-traumatic joint disease, and intervertebral disc degeneration. It is usually described in Khavinson-family publications as the tetrapeptide Ala-Glu-Asp-Leu (AEDL), sometimes written H-Ala-Glu-Asp-Leu-OH or A-E-D-L, though the literature also references slight sequence variants in early publications. Cartalax sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, Bronchogen, and Cardiogen within the Khavinson short-peptide bioregulator family, and is the defined-sequence counterpart to a polypeptide preparation called Sygumir (in some marketing) or cartilage-derived polypeptide complexes from Khavinson's original extract programme. Outside Russia, Cartalax is not registered as a drug, not reviewed by FDA, EMA, or PMDA, and not in any WADA category — though the WADA S0 non-approved substances clause arguably applies for competitive athletes. There are no phase II or phase III RCTs in PubMed or ClinicalTrials.gov, and Cartalax does not appear in OARSI, ACR, or EULAR osteoarthritis guidelines. Published Russian work comprises in vitro chondrocyte culture studies, rodent osteoarthritis model experiments, and small uncontrolled observational series in elderly patients with knee, hip, and spinal osteoarthritis ([Khavinson et al., 2011]; [Chalisova et al., 2014]; [Anisimov et al., 2010]). The central claim for Cartalax is the standard Khavinson short-peptide model applied to cartilage tissue: passive membrane permeation into chondrocytes, nuclear import, sequence-selective chromatin modulation, and preferential upregulation of chondrocyte survival, matrix synthesis (type II collagen, aggrecan, hyaluronic acid), and anti-catabolic programmes (downregulation of MMPs, ADAMTS). The tissue-specificity claim — that AEDL selectively targets cartilage rather than other connective tissue — is asserted but not supported by modern biodistribution, structural biology, or transcriptomics. The hypothesis is internally consistent within the Khavinson programme; it is substantially less validated than the pharmacology of evidence-graded osteoarthritis therapy. BodyHackGuide covers Cartalax because it is sold online in post-Soviet supplement channels (typically 20 mg oral capsules) and appears in longevity-stack discussions alongside joint-support adjuncts. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded joint and cartilage support toward interventions with better replication: weight management (single most impactful intervention for knee OA), structured exercise and physical therapy, NSAIDs where appropriate for symptomatic relief, intraarticular corticosteroid or hyaluronic acid injection, topical NSAIDs, Curcumin and Boswellia for modest anti-inflammatory benefit, collagen peptides and undenatured type II collagen (UC-II) with mixed but some positive evidence, BPC-157 and TB-500 as experimental peptide options with more mechanism data than Cartalax, and surgical intervention (arthroscopy, joint replacement) where indicated. Cartalax is a plausible hypothesis. It is not, in 2026, an evidence-graded cartilage therapy.", "activeIngredient": "Cartalax", "mechanismOfAction": "Mechanism of Action Cartalax's proposed mechanism is the Khavinson short-peptide framework applied to cartilage: passive membrane permeation, nuclear import, and sequence-selective chromatin modulation producing chondrocyte-favourable transcriptional shifts. Step 1 - Tissue distribution. At ~446.5 daltons (H-Ala-Glu-Asp-Leu-OH), Cartalax is small and polar enough to cross phospholipid bilayers passively. Khavinson-group tritiated-peptide biodistribution work (Russian-language literature) describes rapid tissue uptake across cartilage, liver, kidney, and other organs after intraperitoneal or oral administration. Cartilage's unique tissue architecture - avascular, low cellularity with chondrocytes embedded in dense extracellular matrix - raises questions about how efficiently any systemic peptide reaches chondrocyte nuclei. The biodistribution data do not distinguish intact peptide from catabolite signal and do not quantify chondrocyte-level uptake. Step 2 - Chondrocyte targeting. The Khavinson-framework claim is that AEDL reaches chondrocyte nuclei and modulates chromatin in a cartilage-specific manner. No structural biology, no chondrocyte-specific transcriptomic data, and no modern target validation has been published. The mechanistic claim rests on extrapolation from the bioregulator framework. Step 3 - Chromatin modulation of chondrocyte programmes. The framework hypothesises that AEDL increases type II collagen synthesis and aggrecan deposition in chondrocytes and attenuates IL-1-induced MMP-13 upregulation, via preferential activation of chondrogenic transcription factors (SOX9, RUNX2 balance) and anti-catabolic chromatin states. This is a hypothesis, not a demonstrated result: no peer-reviewed chondrocyte study of Cartalax is indexed in PubMed. Modern chondrocyte biology uses iPSC-derived chondrocytes, single-cell RNA-seq of cartilage biopsy samples, and CRISPR-based target validation - none of which has been applied to Cartalax. Alternative conservative framing. A parsimonious interpretation treats Cartalax as an amino-acid source delivering alanine, glutamate, aspartate, and leucine in a rapidly hydrolysed peptide form. Under this framing, biological effects could reflect: (a) leucine-mediated mTOR activation supporting chondrocyte protein synthesis (leucine is a classical mTORC1 trigger with well-characterised kinetics), (b) glutamate/aspartate substrate delivery for TCA cycle anaplerosis in chondrocytes, (c) non-specific amino acid nutritional support. If this framing is correct, leucine supplementation (or branched-chain amino acid mixtures) at far lower cost would produce equivalent effects. Comparison to glucosamine, chondroitin, and collagen peptides. Glucosamine and chondroitin sulphate have been tested in multiple RCTs for osteoarthritis with heterogeneous results - some showing modest symptomatic benefit, others showing no effect above placebo (e.g., the GAIT trial). Collagen hydrolysate peptides (2.5-10 g daily) have small-effect-size positive evidence for OA symptoms, particularly in the knee. Undenatured type II collagen (UC-II) 40 mg daily has small but positive trial data for knee OA. Cartalax sits at a fundamentally different level of specification - hypothesis about chromatin rather than biochemical substrate provision. If Cartalax works purely through amino-acid supplementation, it is inferior to collagen peptides (which provide far more amino acid mass) on cost-effectiveness grounds. Comparison to BPC-157 and TB-500. Among peptide options for cartilage and tendon, BPC-157 and TB-500 have substantially more mechanistic and pre-clinical data in English-indexed literature - BPC-157 with documented angiogenesis and tendon-healing effects, TB-500 with actin-sequestering mechanism and regenerative claims. Neither is FDA-approved or RCT-validated in humans, but both have better-characterised mechanism than Cartalax. In peptide-community hierarchies for connective tissue support, BPC-157 and TB-500 typically rank above Khavinson tetrapeptides. Receptor pharmacology. No GPCR, nuclear receptor, or defined enzyme target identified for Cartalax. It does not engage the IL-1 or TNF pathways directly. It does not inhibit COX-1, COX-2, or LOX. It does not bind cartilage-specific receptors. The absence of a defined pharmacological target is characteristic of the Khavinson framework. Relation to Sygumir and cartilage polypeptide extracts. Cartalax is a synthetic defined-sequence analogue to bovine or porcine cartilage polypeptide extracts sold under various names in post-Soviet supplement channels. Both are positioned as \"cartilage bioregulators\"; Cartalax is the chemically characterised short peptide while extracts are undefined mixtures. Whether the synthetic tetrapeptide recapitulates extract bioactivity is the open question. Overall. Cartalax is a hypothesis-level peptide. Mechanism claims are not validated by modern techniques. If the clinical goal is joint and cartilage support, evidence-graded interventions (weight management, exercise, NSAIDs, collagen peptides, possibly BPC-157/TB-500 with more data) are substantially better-supported.", "dosageForm": "vial", "legalStatus": "Not approved for human use (research chemical)", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is Cartalax and what is it claimed to do?", "acceptedAnswer": { "@type": "Answer", "text": "Cartalax is a synthetic tetrapeptide (Ala-Glu-Asp-Leu, AEDL; ~446.5 Da) from Vladimir Khavinson's St. Petersburg Institute, positioned as a cartilage bioregulator for osteoarthritis, intervertebral disc degeneration, and age-related joint decline. Claims include supporting chondrocyte function, matrix synthesis (type II collagen, aggrecan), and anti-catabolic programmes. These claims trace to Russian-language sources; no peer-reviewed chondrocyte study of Cartalax is indexed in PubMed, and Cartalax has no published human trials - human use is anecdotal only. It is not FDA-approved, not in any OA guideline (OARSI, ACR, EULAR), and not registered as a drug outside Russia. Treat as experimental." } }, { "@type": "Question", "name": "Does Cartalax actually help with osteoarthritis?", "acceptedAnswer": { "@type": "Answer", "text": "Honest answer: the evidence is thin. Cartalax has no published human trials - no controlled trials and no observational series indexed in PubMed; reported benefits (subjective pain reduction, functional improvement over 20-30 day oral cycles in elderly OA patients) are uncontrolled anecdotes from post-Soviet clinical practice, susceptible to placebo response. For osteoarthritis, evidence-graded first-line is weight management (highest impact for knee OA), structured exercise, topical/oral NSAIDs, intraarticular injections when indicated, collagen peptides 10 g daily, and Curcumin. Cartalax is not a substitute for these - it is a tier-12+ experimental adjunct." } }, { "@type": "Question", "name": "What is the correct Cartalax dose?", "acceptedAnswer": { "@type": "Answer", "text": "Khavinson convention: 20 mg oral/sublingual capsule once daily for 10 consecutive days, with 60-90 day washouts. 20 mg capsule contains undisclosed AEDL content (historically 2-4 mg, balance excipients). For subcutaneous synthetic peptide, 2-5 mg daily for 10 days. No dose-ranging trial has established that 20 mg is optimal. Do not exceed 20 mg oral or 5 mg SC daily." } }, { "@type": "Question", "name": "How does Cartalax compare to glucosamine, chondroitin, and collagen peptides?", "acceptedAnswer": { "@type": "Answer", "text": "Glucosamine/chondroitin has heterogeneous RCT evidence - some showing modest benefit, others no effect above placebo (GAIT trial is a key reference). Collagen peptide hydrolysate 10 g daily and undenatured type II collagen (UC-II) 40 mg daily have small-effect-size positive evidence in knee OA. Cartalax sits at a different level of specification - hypothesis about chromatin rather than biochemical substrate provision. On cost-effectiveness and evidence strength, collagen peptides are a better first choice than Cartalax for knee OA symptomatic management." } }, { "@type": "Question", "name": "Is Cartalax safe?", "acceptedAnswer": { "@type": "Answer", "text": "Short-term adverse effects in anecdotal reports are mild - occasional nausea, headache, rare rash - with no serious adverse events described at convention dosing. But the safety base is weak: there are no controlled human trials, documented exposure is limited to uncontrolled anecdotal use, modern pharmacovigilance does not exist, and long-term safety over years of cycles is uncharacterised. Absolute contraindications: pregnancy, breastfeeding, paediatric use, active bone/cartilage malignancy, bone metastases. Use only third-party HPLC-verified product." } }, { "@type": "Question", "name": "Can I stack Cartalax with BPC-157 and TB-500?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, and this is a common peptide-community pattern for joint and tendon issues. BPC-157 250 mcg SC daily and TB-500 2-5 mg weekly have more mechanistic data than Cartalax for connective tissue regeneration. Combining is safe from interaction standpoint but synergy is theoretical. For joint-focused peptide therapy, BPC-157 and TB-500 arguably deserve priority over Cartalax on mechanism strength. Cartalax can layer on top as an adjunct." } }, { "@type": "Question", "name": "How does Cartalax compare to other Khavinson peptides?", "acceptedAnswer": { "@type": "Answer", "text": "Cartalax is the cartilage-specific member of the Khavinson tetrapeptide family, sibling to Pinealon (brain), Thymogen (immune), Vilon (thymus), Livagen (liver), Bronchogen (respiratory), Cardiogen (cardiac), and Epitalon (pineal). All share the passive-permeation-plus-chromatin-modulation mechanistic claim. Cartalax has less published literature than Epitalon or Thymogen, focused on cartilage indications. Evidence base for any member of the family is smaller than evidence for well-studied supplements in the same indications." } }, { "@type": "Question", "name": "Can Cartalax be given intraarticularly?", "acceptedAnswer": { "@type": "Answer", "text": "No Khavinson-convention intraarticular protocol exists. Some peptide-community experimenters attempt intraarticular administration, but without sterility guidance, appropriate concentration data, or physician supervision this is risky. Intraarticular injections are medical procedures - appropriate for corticosteroids, hyaluronic acid, PRP, and similar interventions with validated protocols, not for experimental bioregulators without established intraarticular data. Stick to oral or subcutaneous routes." } }, { "@type": "Question", "name": "Where do I source quality Cartalax?", "acceptedAnswer": { "@type": "Answer", "text": "Supply channels: post-Soviet supplement vendors (20 mg oral capsules, moderate cost, variable quality) and international research-peptide suppliers (lyophilised synthetic AEDL, higher per-mg cost, requires reconstitution). Require third-party HPLC peptide content confirmation and endotoxin testing. Avoid vendors without certificate of analysis. Do not inject intraarticularly from any source." } }, { "@type": "Question", "name": "If I have joint pain and see a BodyHackGuide ad, what should I actually do?", "acceptedAnswer": { "@type": "Answer", "text": "For joint pain and osteoarthritis, the evidence-graded priority list is: (1) weight management if overweight - single highest-impact intervention for knee OA; (2) structured exercise and physical therapy - evidence-graded first-line; (3) topical NSAIDs (diclofenac gel 1%) for localised symptoms; (4) oral NSAIDs (naproxen, celecoxib) as tolerated; (5) intraarticular corticosteroid for acute flares; (6) collagen peptides 10 g daily; (7) Curcumin 500-1500 mg daily with piperine/phytosomal formulation; (8) Boswellia 300-600 mg daily; (9) UC-II 40 mg daily; (10) peptides like BPC-157 and TB-500 as experimental adjuncts with more mechanism data than Cartalax; (11) Cartalax as tier-11+ add-on. Use ads to bring in joint-pain traffic and convert to the evidence-graded content - offer Cartalax only to users who have exhausted proven options." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] ```